p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors

被引:62
作者
Li, Baozong [1 ]
Cheng, Qian [1 ]
Li, Zhenyu [1 ]
Chen, Jiandong [1 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL USA
基金
美国国家卫生研究院;
关键词
p53; p21; PUMA; MDM2; MDMX; germ cell tumor; HUMAN EMBRYONAL CARCINOMA; FAS-MEDIATED APOPTOSIS; CISPLATIN RESISTANCE; ACTIVATION; CANCER; PROTEIN; GENE; PATHWAY; MUTATIONS; AMPLIFICATION;
D O I
10.4161/cc.9.7.11255
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Testicular germ cell tumors (TGCT) are unique in their excellent response to DNA-damaging chemotherapy. Mutation of p53 is rare in both untreated and relapsed TGCTs, suggesting that p53 fails to respond effectively against malignant transformation in germ cells. previous studies implicated the presence of a poorly defined TGCT-specific mechanism of p53 inactivation. Here we show that disruption of p53-mdm2 binding using the MDM2-specific inhibitor Nutlin activates p53 in TGCT cells and is sufficient to induce strong apoptosis. Knockdown of MDMX cooperates with Nutlin to activate p53. Surprisingly, we found that p53 activation induced a two-fold increase in MDMX mRNA and protein expression in TGCT cells. A p53-responsive promoter is identified in MDMX intron 1 that contains a functional p53-binding site, suggesting that MDMX also functions as a negative feedback regulator of p53 in a cell line-dependent fashion. these findings suggest that MDM2 and MDMX are responsible for the functional inactivation of p53 in TGCT. Furthermore, TGCT cells are unique in having a strong apoptosis response to p53. Direct activation of p53 by targeting MDM2 and MDMX may provide a backup approach for the treatment of TGCTs resistant to DNA-damaging drugs.
引用
收藏
页码:1411 / 1420
页数:10
相关论文
共 47 条
[11]  
Gosland M, 1996, PHARMACOTHERAPY, V16, P16
[12]   Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4 [J].
Grier, JD ;
Xiong, SB ;
Elizondo-Fraire, AC ;
Parant, JM ;
Lozano, G .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (01) :192-198
[13]   NO GERMLINE TP53 MUTATIONS DETECTED IN FAMILIAL AND BILATERAL TESTICULAR CANCER [J].
HEIMDAL, K ;
LOTHE, RA ;
LYSTAD, S ;
HOLM, R ;
FOSSA, SD ;
BORRESEN, AL .
GENES CHROMOSOMES & CANCER, 1993, 6 (02) :92-97
[14]   Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation [J].
Houldsworth, J ;
Xiao, H ;
Murty, VVVS ;
Chen, WY ;
Ray, B ;
Reuter, VE ;
Bosl, GJ ;
Chaganti, RSK .
ONCOGENE, 1998, 16 (18) :2345-2349
[15]   Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX [J].
Hu, Baoli ;
Gilkes, Daniele M. ;
Chen, Jiandong .
CANCER RESEARCH, 2007, 67 (18) :8810-8817
[16]   MDMX overexpression prevents p53 activation by the MDM2 inhibitor nutlin [J].
Hu, Baoli ;
Gilkes, Daniele M. ;
Farooqi, Bilal ;
Sebti, Said M. ;
Chen, Jiandong .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (44) :33030-33035
[17]  
Iwato M, 2000, CANCER RES, V60, P2113
[18]   Part II: Testicular cancer - management of advanced disease [J].
Jones, RH ;
Vasey, PA .
LANCET ONCOLOGY, 2003, 4 (12) :738-747
[19]   Role of P53 and MDM2 in treatment response of human germ cell tumors [J].
Kersemaekers, AMF ;
Mayer, F ;
Molier, M ;
van Weeren, PC ;
Oosterhuis, JW ;
Bokemeyer, C ;
Looijenga, LHJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1551-1561
[20]   Inactivation of the p53 pathway in retinoblastoma [J].
Laurie, Nikia A. ;
Donovan, Stacy L. ;
Shih, Chie-Schin ;
Zhang, Jiakun ;
Mills, Nicholas ;
Fuller, Christine ;
Teunisse, Amina ;
Lam, Suzanne ;
Ramos, Yolande ;
Mohan, Adithi ;
Johnson, Dianna ;
Wilson, Matthew ;
Rodriguez-Galindo, Carlos ;
Quarto, Micaela ;
Francoz, Sarah ;
Mendrysa, Susan M. ;
Guy, R. Kiplin ;
Marine, Jean-Christophe ;
Jochemsen, Aart G. ;
Dyer, Michael A. .
NATURE, 2006, 444 (7115) :61-66